Ranbaxy Laboratories (Delisted) share news and announcements
BSE: 500359
Last traded ₹859.80 on 1 Apr 2015
Delisted on 30 Mar 2016.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Ranbaxy Laboratories quarterly results
Jan28Wed
The board met on 28 Jan 2015 to consider results
Notice filed 24 Dec 2014
Inter-alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the third quarter and nine months ending December 31, 2014
Ranbaxy Laboratories annual reports, presentations and earnings calls
The company's own documents, latest first.Ranbaxy Laboratories financials, year by year
Annual reports17
- Annual report, year to Mar 2014 (opens in a new tab)9 Jul 2014
- Annual report, year to Dec 2012 (opens in a new tab)23 Apr 2013
- Annual report, year to Dec 2011 (opens in a new tab)18 Apr 2012
- Annual report, year to Dec 2010 (opens in a new tab)5 Oct 2011
- Annual report, year to Mar 2009 (opens in a new tab)Filing day not known
12 earlier reports
- Annual report, year to Mar 2008 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2007 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2006 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2005 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2004 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2003 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2002 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2001 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2000 (opens in a new tab)Filing day not known
- Annual report, year to Mar 1999 (opens in a new tab)Filing day not known
- Annual report, year to Mar 1998 (opens in a new tab)Filing day not known
- Annual report, year to Mar 1997 (opens in a new tab)Filing day not known
Investor presentations1
Ranbaxy Laboratories share news and announcements
790 announcements, routine notices left out, newest first. Page 1 of 16.
Mar 2015
25 Mar · Suspension of trading in equity shares
Members of the Exchange are hereby informed that the trading in equity shares of Ranbaxy Laboratories Limited shall be suspended w.e.f. April 06, 2015 (i.e. closing hours of trading on April 1, 2015) on account of Scheme of Amalgamation with Sun Pharmaceuticals Industries Limited.25 Mar · Corporate action
Company has fixed Record Date as April 7, 2015 to determine the names of the shareholders of erstwhile Ranbaxy who would be entitled to receive 8 ( eight) equity shares of Re.1 each of the Company for every 10 (ten) equity shares of Rs.5 each of erstwhile Ranbaxy held and to determine the names of the NCD holders who would be entitled to 1 (One) NCD of Rs.1 lac each of the Company for every 1 (One) NCD of Rs.1 lac each held in erstwhile Ranbaxy pursuant to amalgamation of erstwhile Ranbaxy into the Company.9 Mar · Business
Hon’ble High Court of Punjab & Haryana has orally pronounced the Order on March 09, 2015, approving the Scheme of Arrangement involving ....3 Mar · Legal
Ranbaxy Laboratories Ltd has clarified with respect to media report titled "Ranbaxy loses drug pleas in US", which appeared in the Financial Express dated March 1, 2015. "Previously, ....3 Mar · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy loses drug pleas in US". The Company has clarified that "Previously Company has informed the Exchange on November 21, 2014 that the Company had filed a complaint against the US FDA in D.C. Federal Court and in the first instance asking the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided, which was denied. Following that determination, the Court ordered the parties in the suit to prepare and file legal briefs addressing Ranbaxy's request for a preliminary injunction and the defendants request for summary judgment on the merits. Prior to the decision by the Court, FDA rescinded our 180 day exclusivity for Esomeprazole magnesium delayed release capsule 20 mg and 40 mg. This was communicated to the Stock Exchanges vide our Statement dated January 27, 2015. The Court has now issued an opinion indicating that it was (i) denying Ranbaxy's request for preliminary injunction and (ii) granting defendants requests for summary judgment on the merits. In effect, the Court's decision upheld the status quo that FDA had created by rescinding Ranbaxy's tentative approvals and forfeiting our 180 day exclusivities on Valganciclovir and Esomeprazole in November, 2014".2 Mar · Legal
Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "Ranbaxy loses drug pleas in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Feb 2015
Jan 2015
27 Jan · Statement
22 Jan · Disclosure
ESOPs Allotment Committee of Directors at its meeting held on January 22, 2015, allotted 6,40,597 Equity Shares on exercise of stock options ....9 Jan · Shareholding Pattern For December 31, 2014
Dec 2014
24 Dec · Results
Meeting of the Board of Directors of the Company will be held on January 28, 2015, inter alia, to consider and approve Standalone and Consolidated ....24 Dec · Board meeting
Inter-alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the third quarter and nine months ending December 31, 201412 Dec · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "EU bans imports from Ranbaxy Unit". The Company has clarified that "The European Medical Agency (EMA) has been referred to as European Authorities in our statement. Further, as informed earlier the Company had decided to stop manufacturing cephalosporin injectables at Dewas much before the inspections by EMA in June, 2014".11 Dec · Legal
Exchange had sought clarification with respect to the following statement of Ranbaxy Laboratories Ltd on December 8, 2014 : "On December 5, 2014, a jury sitting in the United ....9 Dec · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to announcement dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased with this verdict, and is committed to serving patients, prescribers and the US healthcare system". On basis of above Company had required to clarify following - 1. Details of settlement - material terms of settlement, compensation/penalty paid (if any) and impact of such settlement on financial position of company. The Company vide email dated December 9, 2014 has submitted the clarification as "The Company has not entered into any fresh Settlement Agreement. The law suits pertains to Agreements entered into by Ranbaxy with AstraZeneca in April, 2008. The Company had made a disclosure about these Agreements to the Stock Exchanges vide Press Release dated April 15, 2008 titled Ranbaxy and Astrazeneca reach Agreement in Esomeprazole Patent Litigation . These Agreements were subject matter of anti-trust litigation in the US. The United States District Court for the District of Massachusetts has issued a verdict in favour of the Company. The Company has not paid any compensation/penalty in the matter."8 Dec · Legal
Exchange has sought clarification from Ranbaxy Laboratories Ltd with respect to statement submitted by the Company on December 08, 2014. Ranbaxy Laboratories Ltd is requested ....8 Dec · Legal
Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to announcement dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased with this verdict, and is committed to serving patients, prescribers and the US healthcare system". On basis of above Company is required to clarify following - 1. Details of settlement - material terms of settlement, compensation/penalty paid (if any) and impact of such settlement on financial position of company. The response of the Company is awaited.8 Dec · Statement
5 Dec · Legal
Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "EU bans imports from Ranbaxy Unit". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.4 Dec · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Germany bans Ranbaxy drug". The Company has clarified that "The news item is misleading and we wish to clarify as follows in order to place it in the right perspective. The development pertains to only the Company s cephalosporin injectable unit at Dewas in Madhya Pradesh. The European authorities along with those from Australia and Canada carried out an inspection in June 2014 of all the facilities in Dewas. Well before that time, the Company had decided, to stop producing cephalosporin injectables at Dewas. Since then, the agencies have approved all our facilities for manufacturing Dosage Forms and APIs (Active Pharmaceutical Ingredients) at Dewas including that for oral cephalosporins with the only exception of the cephalosporin injectable unit. We wish to state that Ranbaxy's decision to discontinue manufacture of Cephalosporin injectables would not have a significant impact on the business. Further, we wish to clarify that the current approvals cover all other facilities (Dosage Forms and APIs) at Dewas, including those producing penem API & injections and oral cephalosporins".4 Dec · Legal
Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "Germany bans Ranbaxy drug". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.4 Dec · Legal
Exchange has sought clarification from Ranbaxy Laboratories Ltd with respect to news article appearing on ET Now on December 03, 2014 titled "Germany bars antibiotic drug from Ranbaxy's ....3 Dec · Legal
Exchange has sought clarification from Ranbaxy Laboratories Ltd with respect to news article appearing on ET NOW on December 03, 2014 titled "Germany bars antibiotic drug from Ranbaxy's ....2 Dec · Legal
Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "CCI wants changes to Sun-Ranbaxy deal". The Company has clarified that "we are in communication with the Competition Commission of India (CCI) on specific products and as of now have not received any final order from the CCI regarding divestment of the products".2 Dec · Legal
Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "CCI wants changes to Sun-Ranbaxy deal". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
How the price met the news
The first session after each announcement, beside the market. Moves to 25 May 2009 are on BSE closes, before the company traded on NSE.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 18 Mar 2014Credit ratingup 0.61%+0.1 pts vs Nifty 500market median 0.0% · five sessions +1.5% · volume 0.7× usual
- 30 Sep 2013Credit ratingdown 1.11%+0.3 pts vs Nifty 500market median 0.0% · five sessions +14.3% (+12.8 pts vs Nifty 500) · volume 0.2× usual
- 22 Feb 2011Dividenddown 3.32%−2.4 pts vs Nifty 500market median 0.0% · five sessions −14.6% (−11.1 pts vs Nifty 500) · volume 4.4× usual
- 15 Feb 2011Dividenddown 0.16%−0.6 pts vs Nifty 500market median 0.0% · five sessions −1.5% (−2.4 pts vs Nifty 500) · volume 1.0× usual
- 27 Jan 2011Board or managers changeddown 3.97%−2.3 pts vs Nifty 500market median 0.0% · five sessions −4.3% (+0.6 pts vs Nifty 500) · volume 1.9× usual
- 25 May 2009Board or managers changedup 20.73%+19.3 pts vs Nifty 500market median 0.0% · five sessions +26.2% (+19.5 pts vs Nifty 500) · volume 11.0× usual
- 19 Dec 2008Board or managers changeddown 0.64%−1.6 pts vs Nifty 500market median 0.0% · five sessions −0.8% (+4.9 pts vs Nifty 500) · volume 1.2× usual
- 16 Dec 2008Board or managers changedup 2.50%+0.1 pts vs Nifty 500market median 0.0% · five sessions +3.8% (+1.1 pts vs Nifty 500) · volume 1.4× usual
- 28 Mar 2008Dividendup 0.79%−2.0 pts vs Nifty 500market median 0.0% · five sessions +2.6% (+3.1 pts vs Nifty 500) · volume 0.8× usual
- 18 Oct 2007Dividendup 0.40%+3.9 pts vs Nifty 500market median 0.0% · five sessions +2.1% (+3.0 pts vs Nifty 500) · volume 3.1× usual
4 earlier announcements
- 27 Apr 2007Board or managers changeddown 0.59%+1.1 pts vs Nifty 500market median 0.0% · five sessions +4.7% (+5.3 pts vs Nifty 500) · volume 1.8× usual
- 9 Apr 2007Board or managers changedup 1.25%−1.1 pts vs Nifty 500market median 0.0% · five sessions −3.5% (−7.8 pts vs Nifty 500) · volume 0.5× usual
- 2 Apr 2007Dividenddown 3.20%+1.1 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−1.3 pts vs Nifty 500) · volume 1.6× usual
- 29 Mar 2007Dividendup 2.08%+1.4 pts vs Nifty 500market median 0.0% · five sessions +2.1% (+2.5 pts vs Nifty 500) · volume 1.0× usual